Stockscreener 앱 받기
38.23
1.70%
-0.6144
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Published on: 2025-08-20 13:12:52 - beatles.ru
Can Xenon Pharmaceuticals Inc. sustain its profitability2025 Market WrapUp & Weekly Chart Analysis and Trade Guides - thegnnews.com
Can Traders Expect Breakout From Xenon Pharmaceuticals Inc. This WeekJuly 2025 Price Swings & Technical Buy Zone Confirmations - kangso.co.kr
Are Xenon Pharmaceuticals’ (XENE) Widening Losses Signaling a Pivotal Shift in R&D Strategy? - simplywall.st
Should you wait for a breakout in Xenon Pharmaceuticals Inc.Treasury Yields & Real-Time Stock Entry Alerts - Newser
Research Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
HC Wainwright Issues Negative Outlook for XENE Earnings - Defense World
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - MSN
Will a bounce in Xenon Pharmaceuticals Inc. offer an exitJuly 2025 Movers & Community Verified Swing Trade Signals - Newser
Identifying reversal signals in Xenon Pharmaceuticals Inc.Weekly Risk Summary & Capital Efficient Trading Techniques - Newser
Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs - MSN
What is William Blair’s Forecast for XENE FY2027 Earnings? - Defense World
Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook - MSN
Why Xenon Pharmaceuticals’ Stock is Climbing - TipRanks
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript - Insider Monkey
Xenon (XENE) Receives a Buy from RBC Capital - The Globe and Mail
Xenon Pharmaceuticals (NASDAQ:XENE) Receives Buy Rating from Chardan Capital - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Royal Bank Of Canada - Defense World
Xenon Pharmaceuticals Inc. Approaches Psychological Resistance LevelFed Meeting & Daily Stock Momentum Reports - beatles.ru
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up on Analyst Upgrade - Defense World
Will Xenon Pharmaceuticals Inc. continue its uptrendQuarterly Investment Review & Intraday High Probability Alerts - Newser
Best data tools to analyze Xenon Pharmaceuticals Inc. stockFree Daily Top Performing Stock Insights - Newser
TD Cowen Reaffirms Their Buy Rating on Xenon (XENE) - The Globe and Mail
Xenon Completes Patient Recruitment for Phase 3 Study - The Globe and Mail
Xenon Pharmaceuticals: Azetukalner's 2026 Data Readouts and Multi-Indication Launch Potential - AInvest
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha
Catalyst Pharmaceuticals shares rise 2.54% intraday after Xenon Pharmaceuticals reports positive Phase 3 study progress and commercial leadership appointment. - AInvest
Xenon Pharmaceuticals shares rise 7.40% intraday after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest
Xenon Pharma Q2 2025 Earnings Preview - MSN
RBC Capital Adjusts Price Target on Xenon Pharmaceuticals to $55 From $57, Maintains Outperform Speculative Risk Rating - MarketScreener
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $57 From $60, Maintains Buy Rating - MarketScreener
Xenon Pharmaceuticals: Promising Clinical Developments and Strategic Positioning Support Buy Rating - TipRanks
Xenon Pharmaceuticals shares rise 7.04% premarket after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest
Xenon Pharmaceuticals: Q2 Earnings Snapshot - Huron Daily Tribune
Compass Pathways shares fall 2.53% premarket after Xenon Pharmaceuticals reports Q2 2025 financial results. - AInvest
Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Xenon Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights - AInvest
Xenon Pharmaceuticals' Q2 2025: Navigating Contradictions in X-TOLE2 Enrollment, Dosing, and Safety Strategies - AInvest
Xenon Pharmaceuticals jumps after massive earnings beat By Investing.com - Investing.com South Africa
Is a relief rally coming for Xenon Pharmaceuticals Inc. holders5-Year Price Trend Summary and Analysis - Newser
Xenon Pharmaceuticals' Azetukalner: A High-Potential Biotech Catalyst Ahead of 2026 Topline Data - AInvest
Nova Ltd. shares rise 2.00% after-hours following Xenon's positive Phase 3 study updates and new appointments. - AInvest
Xenon Pharmaceuticals jumps after massive earnings beat - Investing.com
Transcript : Xenon Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Has Xenon Pharmaceuticals Inc. found a price floorMomentum Prediction Based on AI Backtesting - Newser
Xenon Pharmaceuticals reports Q2 EPS $1.07 vs. (75c) last year - TipRanks
Xenon Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Xenon Pharmaceuticals Q2 Loss Widens, CFO Changes Announced - AInvest
Xenon Pharmaceuticals' Q2 2025 Earnings: A Catalyst for Neuroscience Innovation and Shareholder Value - AInvest
Xenon Pharmaceuticals Q2 Loss Widens - MarketScreener
Xenon Reports Second Quarter 2025 Financial Results & Business Update - The Manila Times
Xenon Pharmaceuticals: A High-Conviction Play in Neurological Therapeutics with Azetukalner in Late-Stage Development - AInvest
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Signal strength of Xenon Pharmaceuticals Inc. stock in tech scannersFree Consistent Income Focused Trade List - Newser
Is Xenon Pharmaceuticals Inc. a candidate for recovery playDay Trading Setup Forecast with Trend Model - Newser
Institutional scanner results for Xenon Pharmaceuticals Inc.AI Intraday Market Movement Prediction Tool - Newser
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Natixis Advisors LLC - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsInvestment Timing Strategy with Market Filters - Newser
1.10%
0.04%
자본화:
|
볼륨(24시간):